Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Kim Mulvihill (2009-03-05)
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial Altimmune
These findings largely align with whats been seen with tirzepatide and other GLP-1based medications, including small risks of pancreatitis and gallbladder issues, dose-related gastrointestinal side effects, and discontinuation due to tolerability
Individuals with type 2 diabetes and obesity face a high risk for developing cardiovascular disease and experiencing major cardiac events or conditions, including myocardial infarction, stroke, heart failure, cardiovascular death, and peripheral arterial disease
US$ 22.65
US$ 23.40
US$ 26.03
US$ 21.38
